Compare BridgeBio Pharma Inc (BBIO) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares MSCI Singapore ETF — how do they compare? BridgeBio Pharma Inc trades at $84.55 (market cap $16.36B), while iShares MSCI Singapore ETF trades at $33.63. Which is the better fit depends on your goals.
| BBIO | EWS | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $33.92 |
52-Week Low | $47.29 | $26.71 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
EWS, the iShares MSCI Singapore ETF, trades at $33.68, up 1.54% today and near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though oscillators signal overbought conditions. The ETF benefits from Singapore's economic resilience, AI-driven growth prospects, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026 (SEC filing, 2026-08-05).
Outlook is positive due to Singapore's market reforms and AI infrastructure investments, but risks include concentrated financial sector exposure and regional economic volatility. The bullish technical setup and institutional accumulation support upside potential, though overbought RSI levels warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
